TXG:NASDAQ10x Genomics, Inc. Analysis

TXG is trading at $32.77, comfortably above its 20‑day SMA ($28.49) and 50‑day SMA ($24.91), indicating short‑term momentum. The 200‑day SMA sits at $18.91, reinforcing a long‑term bullish bias. RSI is at 66.9, still below the overbought threshold, while the MACD line (2.13) sits above its signal (2.02), producing a bullish histogram. The stock currently respects a support level near $20.88 and faces resistance around $35.65, leaving modest upside in the near term. Volume has remained stable, but 30‑day volatility is high at ~70%, and beta exceeds 2, pointing to pronounced price swings. These technical cues suggest continued upward pressure, yet price remains close to the upper band of its recent range.
On the fundamentals side, revenue slipped 2.6% year‑over‑year and the company posted a negative operating margin (‑11.3%) and a trailing EPS of –$0.17. Forward earnings are projected at $0.20, inflating the forward P/E to 163.9 versus an industry average of 24.7, signaling substantial overvaluation. A discounted cash‑flow model values TXG at roughly $16.5, implying a downside of over 20% from current levels. The balance sheet is solid, with $540 M in cash offsetting $81 M of debt, and free cash flow remains positive at $124 M. The recent acquisition of Proteintech Genomics expands the proteomics portfolio, but management cautioned that it will not materially affect near‑term guidance. Notably, insider selling by the CEO adds a negative sentiment flag, even as 13 analysts maintain a “buy” consensus with target prices around $25.